Working... Menu
Trial record 25 of 109 for:    stromal vascular fraction

Use of Autologous Adipose-Derived Stromal Vascular Fraction To Treat Osteoarthritis of Hip, Knee, Ankle, and Thumb Joints

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03166410
Recruitment Status : Recruiting
First Posted : May 25, 2017
Last Update Posted : April 11, 2019
Information provided by (Responsible Party):
Jaime R. Garza, MD, Texas Plastic Surgery

Brief Summary:
This study will examine the safety and efficacy of autologous adipose-derived stromal vascular fraction (SVF) cells for treatment of hip, knee and thumb osteoarthritis (OA); monitoring adverse events and measuring pain, function and stiffness in the joints of osteoarthritic subjects.

Condition or disease Intervention/treatment Phase
Osteoarthritis Procedure: Cell injection Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 500 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Use of Autologous Adipose-Derived Stromal Vascular Fraction To Treat Osteoarthritis of Hip, Knee, Ankle, and Thumb Joints
Actual Study Start Date : January 2017
Estimated Primary Completion Date : July 2019
Estimated Study Completion Date : January 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Arm Intervention/treatment
Experimental: Cell Treatment Procedure: Cell injection

Primary Outcome Measures :
  1. Safety - Incidence of Treatment-Emergent Adverse Events [ Time Frame: 1 year ]
    Subjects will be monitored for adverse events

Secondary Outcome Measures :
  1. Efficacy - Change in Pain Scores at All Follow-up Visits [ Time Frame: 3 months, 6 months, 1 year, 2 years ]
    Pain scores will be collected at all visits

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   25 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Grade II through Grade IV hip, knee, ankle osteoarthritis using Kellgren-Lawrence grading scale (K-L Grade) as diagnosed using weight bearing X-ray, physician review, and/or pre-op MRI
  2. Stage II through IV carpometacarpal (CMC) osteoarthritis using Eaton-Little's staging of CMC OA as diagnosed by X-ray and physical examination
  3. Study Subjects must be willing to voluntarily give written Informed Consent to participate in the study and sign the Health Insurance Portability and Accountability Act (HIPAA) authorization before any study procedures are performed
  4. Subjects with ASA grade I, II, or III
  5. Males and females 25-85 years old
  6. Subjects must have continued pain in their targeted/treatment joint despite conservative therapies for at least 3 months

Exclusion Criteria:

  1. Subjects that are allergic to lidocaine, epinephrine or valium
  2. Subjects with a history of bleeding disorders, anticoagulation therapy that cannot be stopped as follows prior to injection; Thrombolytics and anti-platelet medication including but not limited to Coumadin (warfarin) for 3 days, Plavix (clopidogrel) for 3 days, acetylsalicylic acid (ASA)/NSAIDs/fish oil supplements for 7 days, Xeralta® (rivaroxaban) for 24 hours
  3. Subjects with systemic immunosuppressant use within six (6) weeks from screening and subjects with HIV/viral hepatitis
  4. Subjects with chondrocalcinosis, Paget's disease and Villonodular synovitis
  5. Women that are pregnant or planning to become pregnant during the study
  6. Subjects on long term use of oral steroids
  7. History of any chemotherapy or radiation therapy on the targeted/treatment joint or adipose harvest site

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03166410

Layout table for location contacts
Contact: Texas Plastic Surgery

Layout table for location information
United States, Texas
Texas Plastic Surgery Recruiting
San Antonio, Texas, United States, 78240
Sponsors and Collaborators
Texas Plastic Surgery

Layout table for additonal information
Responsible Party: Jaime R. Garza, MD, Principal Investigator, Texas Plastic Surgery Identifier: NCT03166410     History of Changes
Other Study ID Numbers: SVFOA-01
First Posted: May 25, 2017    Key Record Dates
Last Update Posted: April 11, 2019
Last Verified: April 2019

Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis, Hip
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases